Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015

Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)

Published:2019-01-22 Issue:2 Volume:29 Page:137-149
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

He Xingrui¹²³,Chen Xiabin¹²³,Zhang Hancheng⁴,Xie Tian¹²³^ORCID,Ye Xiang-Yang¹²³^ORCID

Affiliation:

1. Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China

2. Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China

3. Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China

4. Drug Discovery, Hangzhou Innogate Pharma Co., Ltd, Hangzhou, Zhejiang Province, China

Funder

National Science Foundation of China

Key Project of Zhejiang Province Ministry of Science and Technology

Key Project of Hangzhou Ministry of Science and Technology

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2019.1567713

Reference47 articles.

1. JAKS AND STATS: Biological Implications

2. Signaling through the JAK/STAT pathway, recent advances and future challenges

3. Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

4. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

5. An Update on JAK Inhibitors

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure–activity relationship;Bioorganic Chemistry;2024-11

2. Janus Kinases and Autoimmunity: Bridging Pathways to Therapy;International Journal of Drug Discovery and Pharmacology;2024-06-05

3. Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis;Indian Journal of Dermatology, Venereology and Leprology;2024-06-03

4. Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan;Journal of Dermatological Treatment;2024-02-02

5. TARGETING SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES;Medicinal Chemistry Reviews;2023-11-16